Organon and Dyax will work together to discover and develop human therapeutic antibodies for the treatment of autoimmune diseases and cancer. Dyax will utilize its phage-display technology to find antibodies directed toward a target identified at Organon’s research center in Cambridge, MA.
“It is our strategy to expand the portfolio of commercially attractive biotech products,” remarks David Nicholson, executive vp R&D of Organon. “Dyax’ state-of-the-art phage-display technology will help us to strengthen our R&D pipeline of antibody therapies for cancer and autoimmune disorders.”
According to the terms of the collaboration, Dyax will receive license fees and research funding as well as milestone payments and royalties.